# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001131399-26-000006
**Filing Date:** 2026-3
**Character Count:** 2511
**Document Hash:** 95a152f1470790e057f12e9ed03e9916
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001131399-26-000006.hdr.sgml**: 20260306

**ACCESSION NUMBER**: 0001131399-26-000006

**CONFORMED SUBMISSION TYPE**: IRANNOTICE

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260306

**DATE AS OF CHANGE**: 20260306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** IRANNOTICE
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 26728716

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG
- **BUSINESS PHONE:** 44 20 8047 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

![image.jpg](image.jpg)

![image_1.jpg](image_1.jpg)

GSK plc

79 New Oxford Street

London

WC1A 1DG

T +44 (0)20 8047 5000

March 6, 2026

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Ladies and Gentlemen,

**Re: Notice of disclosure filed in Securities Exchange Act Annual Report under Section 219 of the** 

**Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities** 

**Exchange Act**

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section

13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that GSK plc has

made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended

December 31, 2025, which was filed with the Securities and Exchange Commission on March 6, 2026.

The disclosure can be found on page 285 of the 2025 Annual Report on Form 20-F, under the heading

"Section 13(r) of the Exchange Act".

Respectfully submitted,

---

| | |
|:---|:---|
| GSK plc | GSK plc |
| By: | /s/ Julie Brown |
| Name: | Julie Brown |
| Title: | Chief Financial Officer |

---

Registered in England & Wales

Company Number : 03888792

Registered Office : 79 New Oxford Street, London, WC1A 1DG